Aurora Cannabis Acquires 20% Stake in Softgel Manufacturer in Exchange for $10M Investment | CashCropToday
0 Shares 676 Views

Aurora Cannabis Acquires 20% Stake in Softgel Manufacturer in Exchange for $10M Investment

June 7, 2018
676 Views

Aurora Cannabis Inc. (TSX: ACB) (OTCQB: ACBFF) announced this morning that the company has acquired a 20% ownership interest in softgel manufacturing and development company Capcium Inc. in exchange for a $10 million dollar investment into the company.

Capcium, is a privately-owned softgel manufacturing company located in Canada. Capcium specializes in the production of high-precision dosage controlled softgels containing cannabinoids. The company has extensive experience in pharmaceuticals and encapsulation.

Capcium will be using the $10 million dollar investment to expand the companies operations and is expected to construct a state-of-the-art product development and manufacturing facility that will be completed in Q4 2019. The facility will help streamline manufacturing time and will be located by Aurora’s manufacturing operation in Quebec.

Aurora Cannabis CEO Terry Booth gave this statement in the press release:

“This investment in Capcium reflects our strategic objective to further expand our differentiated, higher-margin product offerings. Capcium’s extensive know-how has enabled it to develop an advanced technology for the high-volume production of cannabis-based softgels.”

You may be interested

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon
Market Watch
278 views
Market Watch
278 views

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon

Editor - November 27, 2018

Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition
Global
196 views
Global
196 views

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition

Editor - November 26, 2018

Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials
Manufacturing
193 views
Manufacturing
193 views

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials

Editor - November 26, 2018

GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…

Leave a Comment

Your email address will not be published.

Most from this category

%d bloggers like this: